Christina Dold

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8289066/publications.pdf

Version: 2024-02-01

1039880 1474057 5,595 9 9 9 citations h-index g-index papers 13 13 13 11090 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. Lancet Microbe, The, 2022, 3, e21-e31.	3.4	131
2	Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses. JCI Insight, 2022, 7 , .	2.3	24
3	Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet, The, 2021, 397, 881-891.	6.3	979
4	T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses. Nature Communications, 2021, 12, 2055.	5.8	102
5	Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial. Lancet, The, 2021, 397, 1351-1362.	6.3	540
6	Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. Nature Communications, 2021, 12, 5061.	5.8	150
7	Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. Cell, 2021, 184, 5699-5714.e11.	13.5	262
8	Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase $1/2$, single-blind, randomised controlled trial. Lancet, The, 2020, 396, 467-478.	6.3	2,080
9	Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet, The, 2020, 396, 1979-1993.	6.3	1,196